WHO backs weight-loss drugs, urges cheap generics / Photo: Armend NIMANI - AFP/File
-
Authorities to identify Montauk Mary and five other Long Island cold-case victims
-
Davante Adams injury deepens Los Angeles Rams receiver shortage
-
Barbie sequel negotiations stall over reported $25 million pay packages
-
João Franco’s earlier post draws attention after arrest over fatal Turkey brawl
-
Bath & Body Works launches buy-one-get-one-free candle offer
-
Alberta Launches $5M Fund for Women’s Neurology Research to Address Gender Gaps
-
Itlu Arjuna receives U/A certificate ahead of theatrical release
-
Dhananjaya de Silva guides Sri Lanka to 221-4 against Pakistan
-
Niraj Kumar earns Los Angeles Olympic quota with 50m rifle bronze
-
Delhi gold loses Rs 800 while silver falls Rs 5,000
-
India extends micro-credit guarantee plan for five years
-
Madlanga Commission Deadline Extended to 2027 Amid Calls for Structural Justice Reform
-
Pradeep Antony, Smeha Manimegalai portray secret spouses in Mr & Mrs Office
-
Zelenskyy arrives in Dublin for meetings on Ukraine and peace efforts
-
Woman barred from every Greggs outlet after series of offences
-
Jury hears social-media image helped identify teen in Scarlett Faulkner case
-
Ketchup packets link suspect to break-in at Eddie Rocket’s restaurant
-
American Airlines passenger falls ill and vomits on three travellers
-
US Inflation Broadens as Fed Officials Consider Faster Rate Hikes
-
Spain's General Strike Links Housing Crisis to Lost Purchasing Power
-
Euro-Area Inflation Reaches 4% as Energy Prices Jump
-
China's Factory Inflation Accelerates While Consumer Demand Stays Weak
-
US Adds 165,000 Jobs as Unemployment Falls to 4.1%
-
Bank of England Raises Interest Rate to 4% as Energy Risks Intensify
-
Energy Costs Push OECD Inflation Up to 4.5%
-
OPEC Says Oil Output Is Near Prewar Levels Despite Shipping Disruptions
-
China's Trade Surplus Passes $1 Trillion as Technology Exports Surge
-
China's Singles' Day Exposes Persistent Consumer Caution
-
Irish police prepare for further hoax bomb threats after hundreds of schools targeted
-
RBA Inflation Target Origins: Why Australia Chose a Range Over Zero
-
Korea, Singapore and New Zealand Advance Green Trade Pact Talks
-
Ireland and Ukraine consider drone cooperation memorandum after Dublin talks
-
Sister recounts fatal machete attack as Irish murder trial continues
-
Georgia refrigeration company sues EPA after five-year HFC reprieve
-
HoloCoder technology promises brighter smartphone images and 3D depth data
-
EU proposes broad consumer safeguards for apps, subscriptions and ticketing
-
Early Black Friday Walking Pad Deals: Urevo and WalkingPad Discounts
-
Nvidia faces scrutiny over alleged Chinese intelligence link to Jensen Huang
-
Radical Numerics develops offline AI tool to detect engineered pathogens
-
Chennai orders inquiry after dogs die at shelter; two veterinarians face action
-
Kiara Advani Reveals Sidharth Malhotra’s Reaction to Toxic Backlash
-
Startup turns Chennai’s history and culture into an interactive world
-
Four firms compete to design Chennai’s model mobility corridors
-
PodcastOne (NASDAQ:PODC) Reports Record 1H & Q2 Fiscal 2027 Financial Results; 1H Fiscal 2027 Revenue of $31.5M and Adjusted EBITDA* of $2.9M
-
Tires Easy Introduces Monthly Tire Price Index to Track U.S. Replacement Tire Prices
-
Ondas Posts Record Q3 2026 Revenue of $167.5 Million on Strong Bookings and Backlog Growth; Raises Full-Year Outlook
-
Medical Care Technologies Inc. (OTCID:MDCE) Delivers 270% Net Income Surge in Q3 as Profitability Accelerates
-
Ainos Secures Largest Order in Company History: $9 Million ASE Agreement for 5,000 Additional AI Nose Systems
-
NextTrip Advances Cruise Strategy, Connecting JOURNY TV Programming and Digital Booking Tools with Personalized Travel Advisor Support
-
SMX Targets Global Recycling Challenges With AI-Powered Material Intelligence Platform
NYSE - LSE
WHO backs weight-loss drugs, urges cheap generics
The World Health Organization recommended a range of blockbuster weight-loss drugs to treat diabetes and obesity globally for the first time on Friday, calling for cheap generic versions to be made available for people in developing countries.
The new generation of appetite-suppressing drugs called GLP-1 agonists -- which include the brands Ozempic, Wegovy and Mounjaro -- have exploded in popularity due to their ability to help people significantly lose weight.
More than 3.7 million people died from illnesses related to being overweight or obese in 2021 according to WHO figures -- more than top infectious killers malaria, tuberculosis and HIV combined.
However the sky-high prices of GLP-1 drugs, which can cost over $1,000 a month in the United States, have raised concerns they will not be made available in poorer nations where they could save the most lives.
On Friday, the WHO added semaglutide -- the active ingredient in Danish pharma giant Novo Nordisk's Ozempic and Wegovy -- and the liraglutide used in US company Eli Lilly's Mounjaro to its list of essential medicines for adults worldwide.
To ensure these "life-saving" injectable drugs reach people who need them most, the UN agency said in a statement it encouraged "generic competition to drive down prices".
Andrew Hill, a pharmacology researcher at Liverpool University, pointed to research showing that generic semaglutide could be mass produced in India for as little as $4 a month.
"What we're asking is for Novartis and Eli Lilly to do the responsible thing and make their treatments available on a worldwide scale at an affordable, generic price," he told AFP.
The patent for semaglutide will run out in some countries including Canada, India and China next year, which could also result in a surge in generic production.
GLP-1 drugs, which have some side effects including nausea, were originally developed for diabetes, but research has increasingly suggested they could help with a broad range of health problems including addiction.
A study published in the JAMA medical journal this week found that patients with heart problems taking the drugs had more than a 40 percent lower risk of being hospitalised or dying prematurely.
One in eight people worldwide are now obese, while in 2022 more than 800 million people were living with diabetes, according to the WHO.
The WHO also named a range of cancer drugs to its essential medicines list.
M.Fischer--AMWN